KCG
KERX

Knight Capital Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Knight Capital Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$110K Buy
+14,689
New +$115K ﹤0.01% 2920

Other funds holding KERX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MCM
Montibus Capital Management Portland, Oregon $926M AUM

Knight Capital Group's KERX Position: Q2 2013 in Review

Knight Capital Group opened a new position in Keryx Biopharmaceuticals Inc (KERX) in Q2 2013: 14,689 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #2920 among its holdings.

102 funds tracked by Wall St. Rank hold KERX as of Q2 2013.

  • Knight Capital Group held 14,689 shares of Keryx Biopharmaceuticals Inc worth $110K as of Q2 2013.
  • Keryx Biopharmaceuticals Inc was a new Knight Capital Group position in Q2 2013.
  • Keryx Biopharmaceuticals Inc made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #2920 holding.
  • 102 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.